Innate Pharma Regains CD123 Rights, Sanofi Plans Investment
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Collaboration and License Agreement (the...
Tag : Innate Pharma
Innate Pharma Doses First Patient in Phase 1 Study of IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)...